News
Public · Published
Morgan Stanley maintains Neurocrine Biosciences at Equal-Weight, raises price target to $185 from $183
Morgan Stanley kept Neurocrine Biosciences at Equal-Weight, meaning it expects the stock to perform roughly in line with peers, and raised its price target to $185 from $183, a 1.1% increase. That target implies 27.3% upside from the November 2 close of $145.35.
Published:
Updated:
What happened
Morgan Stanley kept Neurocrine Biosciences at Equal-Weight, meaning it expects the stock to perform roughly in line with peers, and raised its price target to $185 from $183, a 1.1% increase. That target implies 27.3% upside from the November 2 close of $145.35.
Confirmed
Global impact / market context
A higher target signals Morgan Stanley sees slightly more value in Neurocrine, though an Equal-Weight rating means it does not expect the stock to beat the broader market. The gap between the $185 target and the $145.35 close shows analysts see room for gains that investors may weigh.
Analyst inference
Other recent analyst targets for Neurocrine range from $150 to $220, so Morgan Stanley's $185 sits in the middle of that spread. The range shows analysts disagree on how much the company's future drug sales are worth, which can make the stock's price more sensitive to news.
Analyst inference
What to watch
- Watch whether other analysts follow Morgan Stanley in raising targets, since five recent notes already range from $150 to $220 and a cluster of higher targets would show growing confidence. Confirmed
- Watch for company updates on drug sales and pipeline progress, because analyst targets like Morgan Stanley's $185 depend on expected future revenue that those updates would confirm or challenge. Proposed
- Watch whether the stock moves toward the $185 target; if it stalls near the $145.35 close, investors may be doubting the growth analysts expect, which could pressure shares. Analyst inference
Evidence
- Original source link unavailable